Quick Takeaways
- TAKEDA PHARMACEUTICAL CO LTD filed SCHEDULE 13G/A for Ovid Therapeutics Inc. Common Stock, par value $0.001 per share (OVID).
- Disclosed ownership: 12%.
- Date of event: 08 Dec 2025.
TAKEDA PHARMACEUTICAL CO LTD - 08 Dec 2025 SCHEDULE 13G/A Report for Ovid Therapeutics Inc. Common Stock, par value $0.001 per share (OVID)
- Filing Manager
- TAKEDA PHARMACEUTICAL CO LTD
- Reporting Manager
- Takeda Pharmaceutical Company Limited
- Symbol
- OVID
- Shares outstanding
- 71,398,341 shares
- Disclosed Ownership
- 8,781,996 shares
- Ownership
- 12%
- Form type
- SCHEDULE 13G/A
- Filing time
- 09 Dec 2025, 21:02:19 UTC
- Date of event
- 08 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"TAKEDA PHARMACEUTICAL CO LTD disclosed 12% ownership in Ovid Therapeutics Inc. Common Stock, par value $0.001 per share (OVID) on 08 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 09 Dec 2025, 21:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 12% | 8,781,996 | 1,781,996 | 7,000,000 | /s/ Max Heuer | Max Heuer / Authorized Signatory | |
| Takeda Pharmaceutical U.S.A., Inc. | 9.8% | 7,000,000 | 0 | 7,000,000 | /s/ Paul Sundberg | Paul Sundberg / Assistant Secretary |